Abstract
BackgroundPatients with advanced renal cell carcinoma with sarcomatoid features (sRCC) have a poor prognosis and limited therapeutic options. First-line nivolumab plus ipilimumab (NIVO+IPI) provided efficacy benefits over sunitinib (SUN) in...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have